Metabolic disease alliances have picked up as companies try to find a spot in the growing obesity market, and earlier this decade the COVID-19 pandemic drove a short-lived uptick in infectious disease alliance dealmaking. But year in and year out, cancer remains the primary driver of partnering and licensing agreements in the biopharmaceutical sector, and a new Biomedtracker report shows 2024 was no exception.
Key Takeaways
- Cancer-driven transactions led the biopharma sector’s alliance dealmaking again in 2024, according to a new Biomedtracker report
The 2024 Deal-making Roundup white paper reports that the industry inked 690 alliance transactions – encompassing licensing agreements, research and development partnerships and asset sales – last year, down 4% from 718 deals in 2023
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?